Resort At Clear Lake Hotel

 NICE Gives Green Light To MabThera(R) (Rituximab) For Wider Use In Patients With Most Common Chronic Leukaemia
The National Institute for Health and Clinical Excellence (NICE) extended its recommendation for the use of targeted antibody MabThera® (rituximab) to include people with relapsed and difficult-to-treat (refractory) chronic lymphocytic leukaemia (CLL) except where patients have received the full therapeutic dose of MabThera in the first line setting or are refractory to fludarabine. CLL is the ...
 NICE Recommends Two New Cancer Drugs This Month
In final guidance published today, NICE is pleased to be able to recommend two new treatments; for inoperable advanced gastric cancer and for non small cell lung cancer. Capecitabine (Xeloda, Roche Products) is recommended, in combination with a platinum-based regimen, for the first-line treatment of inoperable advanced gastric cancer and gefitinib (Iressa) is recommended for the first-line ...
 NICE Hopes To Help People With Motor Neurone Disease Breathe More Easily
People with motor neurone disease could live longer and more comfortably if their respiratory problems are identified and managed more effectively. This is what NICE is hoping to achieve from its new clinical guideline on the management of non-invasive mechanical ventilation, out yesterday (28 July). There are around 5,000 people in the UK who have motor neurone disease; a degenerative and ...
 New NICE Guideline Set To Encourage Healthcare Professionals To 'Think Delirium' And Take Steps To Prevent It
Individual care by a trained multidisciplinary team can help prevent delirium for those people identified at risk, according to new guidelines published yesterday (28 July). The National Institute for Health and Clinical Excellence (NICE) also recommends health professionals should 'think delirium' whenever people are admitted to hospital or long-term care. This new clinical guideline describes ...